We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of F-star Therapeutics, Inc. (“F-star” or the “Company”)(NASDAQ: FSTX), in connection with the proposed acquisition of the Company by invoX Pharma (“invoX”) via a tender offer.  Under the terms of the merger agreement, the Company’s shareholders will receive $7.12 in cash for each share of F-star common stock owned.  The transaction is valued at approximately $161 million.

Weiss Law is investigating whether (i) F-star’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $7.12 per-share merger consideration adequately compensates F-star’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, the merger consideration is below the $30.00 median price target set by analysts, and at least one analyst set a price target for the Company of $35 per share, $27.88 above the per-share merger consideration.